Symptoms and impact of symptoms on function and health in patients with chronic obstructive pulmonary disease and chronic heart failure in primary health care

Kersti Theander, Mikael Hasselgren, Kristina Luhr, Jeanette Eckerblad, Mitra Unosson and Ingela Karlsson

Linköping University Post Print

N.B.: When citing this work, cite the original article.

Original Publication:
http://dx.doi.org/10.2147/COPD.S62563
Copyright: Dove Medical Press
http://www.dovepress.com/

Postprint available at: Linköping University Electronic Press
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-109893
Symptoms and impact of symptoms on function and health in patients with chronic obstructive pulmonary disease and chronic heart failure in primary health care

Kersti Theander1,2
Mikael Hasselgren2,3
Kristina Luhr4
Jeanette Eckerblad5
Mitra Unosson5
Ingela Karlsson1

1Department of Nursing, Faculty of Health Science and Technology, Karlstad University, Karlstad, Sweden; 2Primary Care Research Unit, County Council of Värmland, Karlstad, Sweden; 3Department of Medicine, Örebro University, Örebro, Sweden; 4Family Medicine Research Centre, Örebro County Council, Örebro, Sweden; 5Department of Social and Welfare Studies, Faculty of Health Sciences, Linköping University, Linköping, Sweden

Introduction

Chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) are predominant chronic diseases in older people that are expected to increase during the following years.1,2 In 2020, COPD is expected to be ranked as the third disease in terms of mortality,1 and patients with CHF will increase as the population ages.2 Patients with COPD or CHF are characterized by high comorbidity, multiple symptoms, and unmet...
needs. These patient groups are – to a large extent – managed in primary health care (PHC). Since these diagnoses are chronic, symptoms and function are central for the patients’ health experiences. There is a need for new models of care that meet the specific needs of these populations in PHC.

Patients with COPD or CHF have – on average – nine symptoms or more that result from the primary disease, the treatment, comorbidity, or other causes. They have several symptoms in common, such as shortness of breath or dyspnea and lack of energy or fatigue. Many of the symptoms can cause significant distress that may impact on physical and emotional functioning.

Shortness of breath is common and is prevalent in approximately 95% of patients with COPD and 56% among patients with CHF. A large proportion of patients with COPD (62%) report moderate or severe dyspnea in relation to walking distance or climbing. Another frequent and distressing symptom experienced by these patient groups is fatigue, which is estimated to occur in 43%–58% among patients with COPD, and in 50% among patients with CHF. Fatigue limits physical and psychosocial functioning in patients with COPD, while global and physical functioning are most affected in patients with CHF. Anxiety and depressive symptoms are prevalent in both patient groups.

Among patients with COPD, depression varies between 8%–80% and among patients with CHF, 10%–60%. Furthermore, among patients with COPD, 50% experience sleeping problems, which affect the patients’ experience of other symptoms, as well as overall health. These studies suggest that patients with COPD and patients with CHF experience similar symptoms, both physical and psychological, and that the symptoms have an impact on functioning and health.

The great variation in prevalence between studies might be due to different designs and settings. Previous studies on symptoms are mainly performed on hospitalized patient populations suffering from severe COPD or CHF. Younger patients, or patients from outpatient clinics. Furthermore, the guidelines for COPD and CHF are mainly focused on the assessment and management of symptoms specific to the disease, leaving patients with a variety of potentially untreated symptoms. A recent study comparing patients with severe COPD and patients with CHF recruited from outpatient departments reported that only a minority of patients received symptom-related treatment. The lack of studies on patients with COPD or CHF managed in PHC limits direct comparisons and relevance for PHC. A better understanding of these patient groups in PHC is necessary, as it could be hypothesized that the patients experience similar symptoms and that the impact of symptoms – as a consequence – could be managed together. To our knowledge, there is no study reported that compares the symptoms and impact of symptoms on functioning between these patient groups in PHC.

The aim of this study was to compare the symptoms, the impact of symptoms on functioning, and health between patients with COPD and patients with CHF in PHC.

Methods

Study design

The study design was cross-sectional by using a postal questionnaire. The study was approved by the regional ethical review board in Uppsala, Sweden (EPN 2010/223).

Sample

Two patient groups, one with COPD and one with CHF, were recruited from PHC in three counties located in central Sweden. The inclusion criteria were that patients should be registered in the PHC patient administrative systems with diagnosis COPD (International Statistical Classification of Diseases and Related Health Problems [ICD-10] J44) or CHF (ICD 150) during 2008–2009 and be 50 years of age or older. Patients registered with both COPD and CHF diagnoses were excluded.

In total, 8,923 patients with COPD and 9,263 patients with CHF diagnoses were identified in the patient administrative systems during that time period. The search in the patient administrative systems was performed by blinded administrative personnel in each county. As the number of inhabitants varied between the counties, random samples from each diagnosis group from each county were drawn in proportion to the number of inhabitants in each county. There were nearly 1 million inhabitants in the three counties altogether, and the distribution was 27%, 27%, and 46%, respectively of the inhabitants in each county. Therefore, of the 1,200 patients needed from each diagnosis group, approximately 325/325, 325/325, and 550/550 COPD/CHF patients were randomly selected using the PASW Statistical 18 (SPSS Inc., Chicago, IL, USA) from the lists of patients from each county. In total, 1,218 patients with COPD and 1,215 patients with CHF were invited to participate in the study.

Of the selected patients with COPD, eleven had an unknown address, six died during the study period, and three claimed that they did not have COPD – leaving 1,198 qualified for the study. Of these, 437 (36%) responded to the
questionnaire. Of the selected patients with CHF, 20 had an unknown address, 18 died during the study period, and one had no heart failure, leaving 1,176 qualified for the study. Of these, 388 (33%) answered the questionnaire.

Measurements

Background characteristics

Background characteristics consisted of eight items: age; sex; civil status (married/cohabiting or single); education (compulsory comprehensive school, upper secondary school, or university); employed (yes or no); smoker (current, former, or never smoked); years since diagnosis; and self-reported coexisting diseases (yes or no regarding myocardial infarction, atrial fibrillation, angina pectoris, asthma, kidney disease, liver disease, diabetes, cancer, COPD [only CHF group], CHF [only COPD group], or other).

Symptoms

The Memorial Symptom Assessment Scale (MSAS)\textsuperscript{11} measures prevalence (yes or no) of 32 common symptoms (26 physical and six psychological) within a time frame of “during the past week”. MSAS is a valid and reliable instrument that has been used among both patients with COPD\textsuperscript{4} and patients with CHF.\textsuperscript{11}

Fatigue was measured by three questions concerning frequency, duration, and severity during the past month.\textsuperscript{28}

The Hospital Anxiety and Depression Scale (HADS)\textsuperscript{30} assesses anxiety (seven items) and depression (seven items) using a 4-point Likert scale ranging from 0–3. Item scores are summarized, and each subscale score could range from 0–21, respectively. Values from 0–6 indicate no anxiety/depression, 7–10 mild-to-moderate anxiety/depressed mood, and values >10 potential anxiety disorder/depression. HADS is proven to be valid and reliable and has been used among several different patient groups including patients with COPD\textsuperscript{30} and patients in PHC.\textsuperscript{31} Cronbach’s alpha in the present study for the COPD group was 0.90 for the anxiety subscale and 0.85 for the depression subscale. The corresponding figures for the CHF group were 0.90 for the anxiety subscale and 0.84 for the depression subscale.

Impact of symptoms on function

The Medical Research Council dyspnea scale\textsuperscript{32} measures dyspnea in relation to five grades of physical activity that range from 0= “I only get breathless with strenuous exercise” to 4= “I get breathless when I wash myself or get dressed”. The Medical Research Council dyspnea scale is frequently used and has shown validity when tested among COPD patients.\textsuperscript{33} The Fatigue Impact Scale (FIS)\textsuperscript{34} measures limitations due to fatigue in relation to cognitive (ten items), physical (ten items), and psychosocial (20 items) function during the past month. The FIS uses 5-point Likert scales ranging from 0= “no problem” to 4= “extreme problem”. Item scores are summarized. The FIS total score could range from 0–160, the cognitive and physical subscales from 0–40, and the psychosocial subscale from 0–80. The FIS is tested for reliability and used among Swedish COPD patients.\textsuperscript{17} In the present study, Cronbach’s alpha for the COPD group was 0.99 for the total scale, 0.97 for the cognitive, 0.96 for the physical, and 0.97 for the psychosocial subscales. For the CHF group, the parallel figures were 0.99 for the total scale, 0.96 for the cognitive, 0.96 for the physical, and 0.97 for the psychosocial subscales.

The Insomnia Severity Index (ISI)\textsuperscript{34} comprises seven items covering patients’ perceptions concerning: the severity of sleeping problems (three items); satisfaction with sleeping pattern (one item); impact on daily living (one item); noticeability of sleeping problems (one item), and worry/distress related to sleeping problems (one item). Each item is rated on a 5-point scale ranging from 0–4, giving a summarized ISI score that could range from 0–28. A score between 0–7 indicates no clinically significant insomnia, 8–14 points to subthreshold insomnia, 15–21 shows moderate insomnia, and 22–28 indicates severe insomnia. ISI is shown to be a valid and reliable instrument.\textsuperscript{34} In the present study, Cronbach’s alpha was 0.94 for the COPD group and 0.92 for the CHF group.

Health

Global health was measured by two questions. The patients rated their overall psychological and physical health from 1= “very poor” to 5= “very good”. Single questions measuring perceptions of global health have showed validity and reliability.\textsuperscript{35}

Procedure

The questionnaires, an information letter, and a return envelope were sent during November and December 2010. The questionnaires were filled out anonymously but with a code to have the possibility to send reminders. The code list was destroyed after the data collection. Two written reminders were sent 2 weeks apart to those who did not answer the first or second time.

Statistical analysis

Categorical data are expressed by frequencies and percentages, while continuous data are expressed by means and
standard deviations (SD) and by median and quartile 1 to quartile 3 (q1–q3). The chi-square test was used to compare the COPD and CHF groups, and responders and nonresponders, when data were categorical (Fisher’s exact test was used when >25% of the cells had expected counts less than 5); otherwise, the student’s t-test for independent groups was used.

To control for possible covariates, seven sequential logistic regression analyses were performed in regard to statistically significantly different symptom prevalence (no =0 versus yes =1 regarding shortness of breath, cough, dry mouth, problems with sexual interest or activity, swelling of arms or legs, feeling irritable, worrying) between the COPD group and the CHF group. In the first step, background characteristics which differed (P<0.05) between the groups (age [from younger to older]; sex [men versus women]; civil status [married or cohabiting versus single]; employed [no versus yes]; current smoker [no versus yes]; former smoker [no versus yes]), together with number of self-reported coexisting diseases (from fewer to more), were included in the analyses. In the second step, the diagnosis group (COPD versus CHF) was added.

Due to internal missing data, the numbers of subjects in different analyses varied, as indicated in text and tables. When 30% or more of answers on scales (HADS, FIS, and ISI) and subscales were missing, they were excluded. The P-values are two-sided and considered significant if <0.05. The Statistical Package for the Social Sciences software version 20 (SPSS; IBM Corporation, Armonk, NY, USA) was used.

Results

Background characteristics

The COPD group was younger, contained more women, and more patients were married or cohabiting compared to the CHF group. Furthermore, more of the COPD patients were working, and more of them were current or former smokers compared with patients in the CHF group. Many of the patients in both groups had coexisting diseases (self-reported), although there were fewer of them in the COPD group; 71% (n=311/437) compared with 88% in the CHF group (n=342/388; P<0.001). The mean number of coexisting diseases among patients with COPD was 1.33 (SD 1.29) and among patients with CHF 1.71 (SD 1.21; P<0.001). See Table 1.

Analyses comparing responders with nonresponders showed no differences among the patients with COPD regarding age and sex, although the responding patients with CHF were younger (mean 78.05 years [SD 9.35]) than the nonresponders (mean 81.28 years [SD 9.51]; P<0.001). Also, among the responding patients with CHF, there were more men (57%), compared with the nonresponders (47%; P=0.001). Furthermore, the subgroup analysis of age groups among patients with CHF (<85 years and ≥85 years) was performed, due to the differences between the responders and the nonresponders. There was no age difference between
the responders (n=293) and the nonresponders (n=477) in the CHF group <85 years (mean 74.34 years [SD 7.93] versus 75.06 years [SD 7.70]; P=0.218). In the older subgroup ≥85 years, the responders (n=104) were younger than the nonresponders (n=363) (mean 88.51 years [SD 2.83] versus 89.46 years [SD 3.67]; P=0.005).

Comparisons of sex distribution in the same age subgroups showed that there were more men among the responding patients (61%) than among the nonresponders (54%; P=0.040) in the younger CHF group (<85 years). In the older group (≥85 years), there was no statistical difference regarding the proportion of men between the responders and the nonresponders (45% and 38%, respectively; P=0.205).

**Symptoms**
According to the MSAS, the COPD group (n=273/437) experienced more symptoms (mean 11.30 [SD 7.48]) than the CHF group (n=211/388; mean 9.83 [SD 7.63]; P=0.035). Of the 32 symptoms, 16 symptoms were reported by 40% or more by both the COPD and CHF groups (Table 2). When controlling for background characteristics, the sequential logistic regression analyses (Table 3) showed that the patients with CHF were less likely to have the symptoms of shortness of breath, cough, and dry mouth, and more likely to have the symptoms of swelling of arms or legs, than patients with COPD.

There were no statistically significant differences between the groups regarding fatigue (Table 4). More than one-third of the patients – in both the COPD and the CHF groups – experienced fatigue every day, approximately 10% of the patients experienced fatigue for more than 12 hours per day, and more than one-fifth experienced fatigue as one of their worst symptoms.

With respect to anxiety and depression (HADS), there were no statistically significant differences between the groups (Table 4). Also, 75% of the patients with COPD (n=418) had no anxiety, 9% reported mild to moderate anxiety, and 16% had potential anxiety disorders. In the CHF group, 75% (n=366) reported no anxiety, 11% mild-to-moderate anxiety, and 14% had potential anxiety disorder (P=0.359).

The corresponding percentages for depression were, for the patients with COPD (n=419): no depression 80%; mild-to-moderate depressed mood 12%; and 8% had potential depression. Among the patients with CHF (n=367), 77% experienced no depression, 14% reported mild-to-moderate depressed mood and 9% had potential depression (P=0.436).

### Table 2 Prevalence of physical and psychological symptoms in patients with COPD and patients with CHF

<table>
<thead>
<tr>
<th>MSAS*</th>
<th>COPD n=437</th>
<th>CHF n=388</th>
<th>P-valuec</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shortness of breath (37/50)i</td>
<td>331 (83)</td>
<td>249 (74)</td>
<td>0.003</td>
</tr>
<tr>
<td>Cough (50/50)i</td>
<td>287 (74)</td>
<td>178 (53)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Lack of energy (67/52)i</td>
<td>265 (72)</td>
<td>228 (68)</td>
<td>0.282</td>
</tr>
<tr>
<td>Dry mouth (57/51)i</td>
<td>239 (63)</td>
<td>181 (54)</td>
<td>0.015</td>
</tr>
<tr>
<td>Numbness or tingling in hands and feet (61/50)i</td>
<td>201 (54)</td>
<td>192 (57)</td>
<td>0.405</td>
</tr>
<tr>
<td>Pain (64/63)i</td>
<td>194 (52)</td>
<td>181 (56)</td>
<td>0.327</td>
</tr>
<tr>
<td>Feeling drowsy (81/79)i</td>
<td>178 (50)</td>
<td>142 (46)</td>
<td>0.284</td>
</tr>
<tr>
<td>Dizziness (61/57)i</td>
<td>173 (46)</td>
<td>155 (47)</td>
<td>0.951</td>
</tr>
<tr>
<td>Problems with sexual interest or activity (76/86)i</td>
<td>152 (42)</td>
<td>99 (33)</td>
<td>0.013</td>
</tr>
<tr>
<td>Feeling bloated (80/66)i</td>
<td>143 (40)</td>
<td>112 (35)</td>
<td>0.120</td>
</tr>
<tr>
<td>Problems with urination (64/55)i</td>
<td>145 (39)</td>
<td>135 (41)</td>
<td>0.670</td>
</tr>
<tr>
<td>Itching (69/61)i</td>
<td>122 (33)</td>
<td>118 (36)</td>
<td>0.510</td>
</tr>
<tr>
<td>Sweats (65/60)i</td>
<td>119 (32)</td>
<td>97 (30)</td>
<td>0.439</td>
</tr>
<tr>
<td>Nausea (70/65)i</td>
<td>102 (28)</td>
<td>84 (26)</td>
<td>0.533</td>
</tr>
<tr>
<td>Swelling of arms or legs (57/45)i</td>
<td>101 (27)</td>
<td>146 (43)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Lack of appetite (72/60)i</td>
<td>93 (26)</td>
<td>86 (26)</td>
<td>0.834</td>
</tr>
<tr>
<td>Diarrhea (72/63)i</td>
<td>88 (24)</td>
<td>83 (26)</td>
<td>0.745</td>
</tr>
<tr>
<td>Difficulty swallowing (67/62)i</td>
<td>78 (21)</td>
<td>77 (24)</td>
<td>0.436</td>
</tr>
<tr>
<td>Constipation (54/53)i</td>
<td>78 (20)</td>
<td>66 (20)</td>
<td>0.796</td>
</tr>
<tr>
<td>Change in skin (61/59)i</td>
<td>76 (20)</td>
<td>62 (19)</td>
<td>0.635</td>
</tr>
<tr>
<td>Hair loss (57/56)i</td>
<td>60 (16)</td>
<td>50 (15)</td>
<td>0.748</td>
</tr>
<tr>
<td>Vomiting (69/63)i</td>
<td>55 (15)</td>
<td>47 (15)</td>
<td>0.813</td>
</tr>
<tr>
<td>Weight loss (58/50)i</td>
<td>51 (14)</td>
<td>53 (16)</td>
<td>0.320</td>
</tr>
<tr>
<td>Pain in mouth (56/51)i</td>
<td>46 (12)</td>
<td>36 (11)</td>
<td>0.583</td>
</tr>
<tr>
<td>Change in way food tastes (65/54)i</td>
<td>42 (11)</td>
<td>37 (11)</td>
<td>0.942</td>
</tr>
<tr>
<td>“I don’t look like myself” (60/56)i</td>
<td>31 (8)</td>
<td>25 (8)</td>
<td>0.764</td>
</tr>
</tbody>
</table>

**Psychological symptoms**
| Difficulty sleeping (57/57)i | 233 (61) | 188 (57) | 0.208 |
| Feeling irritable (62/58)i | 208 (56) | 151 (46) | 0.010 |
| Worrying (68/66)i | 200 (54) | 150 (47) | 0.047 |
| Feeling nervous (68/62)i | 157 (43) | 130 (40) | 0.448 |
| Feeling sad (70/58)i | 151 (41) | 137 (42) | 0.941 |
| Difficulty concentrating (68/65)i | 149 (40) | 131 (41) | 0.932 |

**Notes:** Symptoms are sorted in descending order, according to prevalence in the COPD group; comparison between the COPD and the CHF groups, chi-square test; or Fisher’s exact test; *number of patients with missing answers, the COPD and the CHF groups, respectively.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; CHF, chronic heart failure; MSAS, Memorial Symptom Assessment Scale.

**Impact of symptoms on function**
There were no statistically significant mean differences between the COPD and the CHF groups in dyspnea in relation to physical activity, functional limitations due to fatigue, or insomnia (Table 5). In the COPD group (n=412/437), 52% had no clinically significant insomnia, 27% were in the range of subthreshold insomnia, 16% had moderate insomnia, and 5% reported severe insomnia. The corresponding figures for
the CHF group (n=358/388) were 51%, 30%, 17%, and 3%, respectively (P=0.316).

Health
The mean scores for global psychological health were 3.59 (SD 1.07) for patients with COPD (n=430/437) and 3.59 (SD 1.08) for those with CHF (n=371/388; P=0.935), while the mean scores for global physical health were 2.90 (SD 1.02) and 2.95 (SD 1.12), respectively (P=0.542).

Discussion
The main results of this study suggest that patients with COPD or CHF in PHC experience many symptoms that are similar. Also, 16 symptoms out of the 32 MSAS symptoms were reported by 40% or more of the patients in both groups. Among the top five prevalent symptoms for both patient groups were shortness of breath, lack of energy, and difficulty sleeping. Differences among the top five prevalent symptoms were cough, dry mouth, numbness or tingling in hands and feet, and pain. Experiences of shortness of breath, cough, and dry mouth were more common in patients with COPD, while the experience of swelling of arms or legs was more common among patients with CHF when controlling for background characteristics. Both COPD and CHF patients had similar functional limitations due to dyspnea, fatigue, and sleeping problems.

Patients with COPD or CHF experience many symptoms. Many of the symptoms in this study have previously been reported, but in isolation and separately for patients with COPD or CHF, making comparisons difficult. The symptom prevalence among the patient groups in this study is comparable with the findings in the studies by Theander et al.
Table 4 Experience of fatigue, anxiety, and depression in patients with COPD and patients with CHF

<table>
<thead>
<tr>
<th></th>
<th>COPD n=437</th>
<th>CHF n=388</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue frequency during last month (28/35)⁷</td>
<td></td>
<td></td>
<td>0.125</td>
</tr>
<tr>
<td>Not a problem</td>
<td>142 (35)</td>
<td>126 (36)</td>
<td></td>
</tr>
<tr>
<td>1–7 days</td>
<td>67 (16)</td>
<td>52 (15)</td>
<td></td>
</tr>
<tr>
<td>8–14 days</td>
<td>29 (7)</td>
<td>15 (4)</td>
<td></td>
</tr>
<tr>
<td>15–21 days</td>
<td>18 (4)</td>
<td>10 (3)</td>
<td></td>
</tr>
<tr>
<td>22–30 days</td>
<td>14 (3)</td>
<td>6 (2)</td>
<td></td>
</tr>
<tr>
<td>Every day</td>
<td>139 (34)</td>
<td>143 (41)</td>
<td></td>
</tr>
<tr>
<td>Fatigue duration per day (38/47)⁷</td>
<td></td>
<td></td>
<td>0.269</td>
</tr>
<tr>
<td>No experience</td>
<td>124 (31)</td>
<td>101 (30)</td>
<td></td>
</tr>
<tr>
<td>&lt;6 hours</td>
<td>164 (41)</td>
<td>123 (36)</td>
<td></td>
</tr>
<tr>
<td>6–12 hours</td>
<td>77 (19)</td>
<td>79 (23)</td>
<td></td>
</tr>
<tr>
<td>13–24 hours</td>
<td>34 (9)</td>
<td>38 (11)</td>
<td></td>
</tr>
<tr>
<td>Fatigue severity (43/52)⁷</td>
<td></td>
<td></td>
<td>0.608</td>
</tr>
<tr>
<td>Not a problem</td>
<td>164 (42)</td>
<td>137 (41)</td>
<td></td>
</tr>
<tr>
<td>One of my least severe symptoms</td>
<td>148 (38)</td>
<td>119 (35)</td>
<td></td>
</tr>
<tr>
<td>One of my worst symptoms</td>
<td>82 (21)</td>
<td>80 (24)</td>
<td></td>
</tr>
</tbody>
</table>

Table 5 Impact of dyspnea, fatigue, and sleep on functioning in patients with COPD and patients with CHF

<table>
<thead>
<tr>
<th></th>
<th>COPD n=437</th>
<th>CHF n=388</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRC dyspnea scale (16/26)⁹</td>
<td></td>
<td></td>
<td>0.720</td>
</tr>
<tr>
<td>Cognitive (23/32)⁹</td>
<td>10.4 (10.1)</td>
<td>11.3 (9.8)</td>
<td></td>
</tr>
<tr>
<td>Physical (20/26)⁹</td>
<td>14.0 (10.9)</td>
<td>15.1 (10.9)</td>
<td></td>
</tr>
<tr>
<td>Psychosocial (19/24)⁹</td>
<td>21.6 (19.6)</td>
<td>23.4 (19.3)</td>
<td></td>
</tr>
<tr>
<td>Total (24/37)⁹</td>
<td>46.2 (39.4)</td>
<td>49.9 (38.6)</td>
<td></td>
</tr>
<tr>
<td>ISI (25/30)³¹</td>
<td>8.5 (7.0)</td>
<td>8.4 (6.5)</td>
<td>0.765</td>
</tr>
</tbody>
</table>

Notes: *Comparison between the COPD and the CHF groups, Student's t-test; ¹number of patients with missing answers, the COPD and the CHF groups, respectively; patients who claimed no fatigue have not answered these questions.
Abbreviations: COPD, chronic obstructive pulmonary disease; CHF, chronic heart failure; MRC, Medical Research Council dyspnea scale; FIS, Fatigue Impact Scale; ISI, Insomnia Severity Index; SD, standard deviation; q, quartile.

Blinderman et al.⁹,¹¹ in which the symptoms were also assessed in patients with COPD or CHF using the MSAS questionnaire. As the patients experience a broad spectrum of symptoms, it is necessary to assess symptoms more broadly than only the disease-specific symptoms. Symptoms such as numbness or tingling in hands and feet, pain, feeling drowsy, dizziness, and difficulty sleeping are symptoms that need to be addressed. Otherwise, the patients may be left with an amount of symptoms that could accelerate and affect each other. However, a low concordance between patients and physicians when assessing symptoms has been found.⁸ It is unclear if the large number of symptoms that patients experience are disclosed during a consultation. This indicates that the assessment of physical and psychological symptoms in these groups of patients should be more comprehensive and individualized.

In this study, the prevalence of shortness of breath, cough, and dry mouth is higher (9%, 21%, 9%, respectively) for patients with COPD. Although there are statistically significant differences, the number of patients that experience the symptoms is high also in the CHF group. Due to different etiology for patient with COPD or CHF, some symptom interventions need to be disease specific; on the other hand, interventions may be similar although different etiology. For instance, patients with COPD or CHF with shortness of breath need specific pharmacological treatment, while recommendations for both patient groups are physical activity.⁵⁵,⁶ Dry mouth in patients with COPD could be related to anticholinergic treatment; whereas, in patients with CHF, it could be related to treatment with diuretics and restriction in fluid intake. Interventions for dry mouth are general, such as glycerol spray and chewing gum.³⁹ As expected, the swelling of arms and feet was more prevalent in patients with CHF.

More than 40% of both patient groups experienced all of the measured psychological symptoms. Feeling irritable and worrying were not related to COPD or CHF when controlled for age, sex, and coexisting disease. Furthermore, there were no significant differences between the patient groups in relation to anxiety and depression. The psychological symptoms seem to be related to other aspects than diagnosis and are multifactorial, particularly in older people. The high prevalence of psychological symptoms must be assessed to avoid for example, social isolation, and nonadherence to medical treatment.⁴⁰ Furthermore, both anxiety and depression are
related to higher exacerbation risk, increased general and emergency care visits, rehospitalization, and higher medical costs in patients with COPD and CHF. Current evidence suggests that pulmonary and cardiac rehabilitation may offer improvement in anxiety and depression.

It is interesting that few patients with COPD and CHF reported nutritional and gastrointestinal specific symptoms. In the guidelines, nutritional interventions are based on malnutrition. For patients with COPD in PHC other interventions, such as balanced diet must be discussed; as pointed out by other researchers recently.

Dyspnea, fatigue, and sleeping problems had similar impact on functioning in both patient groups. Furthermore, psychological and physical health was also similar. The results indicate that only disease-specific management could be a less promising strategy when caring for COPD and CHF patients in PHC. As the patient groups share similar symptoms, impact of symptoms and health and also as COPD and CHF are comorbidities it could be promising for the patients, health care system and costs to combine these groups in a management program. This needs to be further studied. There is evidence that rehabilitation improves the experiences of dyspnea and fatigue in hospital settings in PHC settings, however, it is not proved. In PHC, it is not even common for patients to have access to rehabilitation, symptom management, or education. The goal with nonpharmacological management of COPD and CHF is to improve symptoms and functioning and to promote comprehensive education and counseling. A new paradigm of care that focuses on symptoms and their impact on function and health is needed in PHC. Recently, exercise rehabilitation intervention for both these groups together resulted in similar improvements in exercise performance and health; the rehabilitation consisted of supervised physical training and education. The study included patients from community CHF nurses’ and physicians’ referrals to pulmonary rehabilitation, making it difficult to make generalizations into PHC.

Limitations
This study has strengths and limitations. The patients were classified according to ICD-10. Classification according to ICD-10 is not well-established in PHC; for instance, a recent study has found that 60%–70% of patients with CHF or ischemic heart disease were registered. An interesting – and important – issue to investigate had been the experiences of patients suffering from both COPD and CHF. In this study, very few persons were found who were registered in the patient administrative systems with both diagnoses; therefore, they were excluded. However, the patients were asked in the questionnaire about several potential coexisting diseases, including COPD and CHF. The results according to patients’ self-reported comorbidity suggest that there may be more COPD patients diagnosed with CHF and vice versa than found in the patient administrative systems.

Future research should address the situation for patients who are diagnosed with both of these chronic conditions. Here, self-reported COPD and CHF were treated as other self-reported conditions. Furthermore, overall self-reported comorbidity was low in this study, with mean values of 1.3 (COPD) and 1.7 (CHF), as compared to other studies. In the case where the self-reported comorbidities were underreported by the patients, we have no reason to assume that the underreporting differed in the COPD or CHF groups. Although the number of coexisting diseases could have been underestimated, the symptom prevalence is high and comparable with other studies. Moreover, as expected, the number of comorbidities was a significant variable in all logistic analyses with one exception. The possibility to recruit patients without comorbidity is difficult and is not representative for patients in PHC.

Despite two reminders, the response rates were low – 36% and 33%, respectively – in the two groups. The low response rate could be due to the fact that the patient groups are elderly (in particular, the patients with CHF) and that an extensive questionnaire was used. In future studies, questionnaires with a home interview could be considered in relation to costs and response rate. Cognitive impairment like dementia increases with age, and patients could be unable or unwilling to participate in studies. In the present study, it was not feasible to list cognitive impairment as an exclusion criterion. Also, patients who were seriously ill with many symptoms could have had difficulty completing the questionnaire. The comparisons between the respondents and nonrespondents for the COPD group showed no differences regarding age and sex while the respondents in the CHF group were younger patients and more men. However, age subgroup analysis showed no differences among patients younger than 85 years. This indicates a participant selection bias in that the oldest patients and women with CHF are not fully represented in the study, which should be kept in mind when interpreting the results. Difficulty in recruiting older patients or a disproportionate number of women with CHF has also been found in other studies, which may limit the generalization of the results. The other studies indicate that the results are not overestimated. COPD patients are
normally approximately 10 years younger than CHF patients. The difference in age is most likely the reason for the difference in civil and working status among the groups.

With regard to the study samples, the strength of this study is that it is multicenter; the study samples were randomly selected and separately taken from each of the three counties. The total population of the study samples included all patients (approximately 18,000 patients) in PHC with COPD or CHF in three counties. In spite of a low response rate, the sample size is not small as compared to other studies.9,11,26

Furthermore, the study has sufficient statistical power (90% and P-value of 0.05); for example, a 9% difference of the prevalence of shortness of breath between the groups, required 120 individuals in each group.

Conclusion and implications for practice
The patient groups showed more similarities than differences in terms of symptoms and their impact on function and health – although there were differences in several background characteristics between patients with COPD and patients with CHF. Patients frequently have multiple symptoms, not only disease-specific, that need to be identified and managed both in groups and individually in PHC. It may be difficult to have separate interventions for all chronic diagnoses in PHC. Joint interventions based on symptoms and functioning for patients with these chronic diseases in PHC may offer the best hope for improving symptoms and their impact on function and health.

Future research in PHC should focus more on a holistic approach. This means taking the whole patient into account, including comorbidity that is based on the physician’s diagnosis, and the effects of symptom management programs when combining, for example, patients with COPD and CHF. This study reports the prevalence of symptoms, but more research is needed for the multidimensional symptom approach.

Acknowledgments
This study was funded by: the Department of Research and Public Health in the County Council of Värmland; the Uppsala–Örebro Regional Research Council; and the Swedish Heart and Lung Association.

Disclosure
The authors report no conflicts of interest in this work.

References


